In Vitro Resistance to Macrolides and Clindamycin by Group B Streptococcus Isolated from Pregnant and Nonpregnant Women

Table 2

Distribution (number and percentage) of resistant GBS strains during the 4-year study period.

	2005		2006		2007		2008
	positive cultures (85)		positive cultures (162)		positive cultures (280)		positive cultures (366)
	N °	%	N °	%	N °	%	N °	%
AMC	0	—	0	—	0	—	0	—
AMP	0	—	0	—	0	—	0	—
CEC	0	—	0	—	0	—	0	—
CTX	0	—	0	—	0	—	0	—
CRO	0	—	0	—	0	—	0	—
CLI	14	16.5	48	29.6	162	57.9	256	69.9
ERY	14	16.5	48	29.6	162	57.9	256	69.9
PEN	0	—	0	—	0	—	0	—
TEC	0	—	0	—	0	—	0	—
TET	51	60	97	59.9	197	70.4	278	76
SXT	0	—	0	—	0	—	0	—
VAN	0	—	0	—	0	—	0	—
LVX	0	—	0	—	0	—	0	—
AZM	14	16.5	48	29.6	162	57.9	256	69.9
CLR	14	16.5	48	29.6	162	57.9	256	69.9
Q-D	0	—	0	—	0	—	0	—
LZD	0	—	0	—	0	—	0	—

AMC = amoxicillin-clavulanic acid; AMP = ampicillin; CEC = cefaclor; CTX = cefotaxime; CRO = ceftriaxone; CLI = clindamycin; ERY = erythromycin; PEN = penicillin; TEC = teicoplanin; TET = tetracycline; SXT = trimethoprim-sulfamethoxazole; VAN = vancomycin; LVX = levofloxacin; AZM = azithromycin; CLR = clarithromycin; Q-D = quinupristin-dalfopristin; LZD = linezolid.